SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is trending due to an impending index reclassification decision, which sparks debate among investors regarding potential capital outflows versus a rebound. Community members are closely watching Bitcoin's price action, viewing MSTR as a leveraged proxy for the cryptocurrency, despite discussions around recent significant Q4 losses and ongoing share dilution.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is generating significant community discussion, propelled by anticipation for an upcoming earnings report that is widely expected to showcase robust performance and potential new hyperscaler contracts. Enthusiasm is high within the community, fueled by strong belief in the company's role as a leading data center operator crucial for the AI infrastructure boom, with many discussing a potential short squeeze and the company's strong fundamentals. The early release of the report has intensified this bullish sentiment, positioning the company as a key player in a capacity-constrained market.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron (CVX) is trending amid discussions surrounding recent geopolitical developments in Venezuela, where the potential reopening of massive oil reserves to U.S. companies highlights Chevron's unique operational presence and strategic advantage. The community is actively debating whether this represents a generational opportunity for Chevron and the broader oil sector, with many anticipating significant upward momentum, while others express caution about market overreaction and long-term implications for global supply.

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Zenas Biopharma Inc.

Zenas BioPharma (ZBIO) is generating significant discussion after its Phase 3 INDIGO trial results for obexelimab, which, despite meeting its primary endpoint with a 56% reduction in disease flares, led to a sharp stock decline. The community is actively debating the disconnect between the 'positive' data and the sell-off, with many citing unmet efficacy expectations and the company's confirmed ineligibility for a $75 million royalty milestone payment as key drivers. This has created a polarized outlook, with some investors calling it 'classic biotech' volatility and others viewing the considerable dip as a prime buying opportunity.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trending due to widespread community speculation about its AI software's instrumental role in a recent geopolitical mission, which is seen as a significant validation of its defense and intelligence capabilities. This perceived involvement is driving strong bullish sentiment, with many anticipating increased government contracts and a subsequent stock rally, even as some investors continue to scrutinize its valuation.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is trending due to widespread community discussion surrounding potential US involvement in Venezuela and the prospect of American oil companies, including XOM, re-entering the nation's vast oil reserves. Investors are actively debating whether this geopolitical development signals a major breakout and significant profits for the energy giant or if it will lead to an oversupply that could pressure crude prices.

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

GH Research PLC

GH Research (GHRS) is experiencing a surge in conversation after the FDA lifted the clinical hold on its GH001 program for treatment-resistant depression, clearing the path for U.S. clinical trials and a global Phase 3 initiation. This pivotal development, building on strong Phase 2b data showing significant remission rates, has ignited considerable bullish sentiment among investors. The community is actively discussing the stock's potential for substantial upside and new highs, positioning GHRS as a key player in the evolving psychedelic therapeutics sector.

Momentus, Inc. engages in the provision of in-space infrastructure services. It offers space transportation and in-orbit servicing. The company was founded by Mikhail Kokorich in 2017 and is headquartered in Santa Jose, CA.

Momentus Inc - Ordinary Shares - Class A

Momentus Inc. is generating buzz following news of its additive-manufactured fuel tank development for the Vigoride-7 orbital vehicle, slated for a SpaceX mission, alongside its role in U.S. Space Force initiatives. The community is sharply divided, with some anticipating a significant short squeeze fueled by an exceptionally low share float in the hot space sector, while others express caution due to the company's past reverse splits and dilution. This volatility is amplified by its connections to major players like SpaceX, NASA, and projects like the "Golden Dome."

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending following the finalization of its Ask Sage acquisition, bolstering its secure generative AI offerings for defense and regulated sectors. The market is also digesting news of significant debt reduction, involving a share conversion, with community sentiment split between optimism for future government contracts and concerns over potential dilution from expanded authorized shares. Many see the company as a key player in critical AI infrastructure, often drawing comparisons to Palantir, while others remain cautious given past stock volatility.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending after receiving a significant analyst upgrade, fueling discussions around its strategic vision to become an "everything exchange" for crypto and traditional assets. The community is actively debating the stock's potential for further upside and a performance rebound, driven by strengthening sentiment across the broader crypto market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Unicycive Resubmits NDA For Oxylanthanum Carbonate To FDA

(RTTNews) - Unicycive Therapeutics, Inc. (UNCY) on Monday said it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for oxylanthanum carbonate (OLC) for the...

Vivo Capital LLC Has $5.42 Million Stock Position in Unicycive Therapeutics, Inc. $UNCY

Vivo Capital LLC lowered its position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 90.0% in the second quarter, according to its most recent 13F filing with the Securities...

Unicycive Therapeutics (NASDAQ:UNCY) Trading Up 5.6% - Time to Buy?

Unicycive Therapeutics (NASDAQ:UNCY) Trading 5.6% Higher - Time to Buy...

UNCY FY2025 EPS Boosted by Brookline Capital Management

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Research analysts at Brookline Capital Management boosted their FY2025 EPS estimates for Unicycive Therapeutics in a research report issued...

HC Wainwright Has Positive Outlook for UNCY FY2029 Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Research analysts at HC Wainwright boosted their FY2029 EPS estimates for Unicycive Therapeutics in a research note issued to investors on...

Unicycive Therapeutics (NASDAQ:UNCY) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.33) earnings per share for the quarter, beating the consensus...

UNCY Deadline Today: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March...

Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY

Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the...

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ: UNCY) and reminds investors of...

UNCY LAWSUIT ALERT: Levi & Korsinsky Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

UNCY LAWSUIT ALERT: Levi & Korsinsky Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline UNCY LAWSUIT ALERT: Levi & Korsinsky Notifies Unicycive...

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

UNCY
Unicycive Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest UNCY News

UNCYUnicycive Therapeutics Inc